Thelansis

  Current therapies for adults with newly diagnosed B-ALL have complete remission (CR) rates of 60%–90%. In relapsed or refractory (R/R) B-ALL cases, chemotherapy achieves CR rates of 31%–44% during first salvage therapy and 18%–25% during second salvage therapy. For patients who achieve a second CR after re-induction chemoimmunotherapy, allogeneic hematopoietic cell transplantation (HCT) remains the standard of care. The absence of measurable residual disease (MRD) in the marrow after intensive multi-agent cytotoxic chemotherapy is the most predictive factor for better clinical outcomes in B-ALL. Persistent MRD at the time of allogeneic HCT is associated with higher relapse rates. Historically, treatment options for R/R B-ALL were limited to conventional cytotoxic chemotherapies, resulting in CR rates of 30%–40% for the first salvage and 10%–20% for the second salvage. This has driven the development of novel therapies to improve outcomes in adult R/R ALL. Antibody-targeted ther...